CoreMap raises $37 million Series C led by Medtronic

CoreMap closed an oversubscribed $37 million Series C financing on July 29, 2026, with Medtronic leading the round. The Burlington, Massachusetts company plans to use the capital to speed development of its next-generation atrial fibrillation mapping platform, which aims to give electrophysiologists more precise guidance for AF ablation.

Why it matters: - Atrial fibrillation is one of electrophysiology’s hardest treatment problems, and better mapping tools could help physicians make more targeted ablation decisions. - The new financing gives CoreMap more runway to bring its AF mapping platform to market faster. - Medtronic’s lead investment signals commercial interest in more data-driven approaches to AF treatment.

What happened: - CoreMap closed a $37 million Series C financing on July 29, 2026. - The round was oversubscribed. - Medtronic led the financing. - Existing and new investors also participated. - CoreMap is based in Burlington, Massachusetts. - The company develops advanced tools for the diagnosis and treatment of atrial fibrillation.

The details: - CoreMap’s platform uses proprietary high-density mapping technology and advanced data analytics. - The company is developing an electrophysiology mapping system designed to guide AF ablation using large data sets of highly accurate electrical activation data. - CoreMap was founded in 2016. - The company is privately held. - Sarah Kalil is CoreMap’s chief executive officer and co-founder. - Chris Eso is global head of corporate and business development, M&A and ventures at Medtronic. - Kalil said the financing will help accelerate the next-generation AF mapping platform’s time to market. - Medtronic said CoreMap is addressing a critical unmet need in AF treatment with a differentiated technology platform and strong clinical support.

Between the lines: - The oversubscribed round suggests investor demand exceeded the amount CoreMap set out to raise. - Medtronic’s participation may help validate CoreMap’s technology in a market where clinical evidence and workflow fit matter as much as engineering. - CoreMap is positioning its platform around a simple clinical promise: clearer AF data for more personalized treatment.

What's next: - CoreMap plans to use the new capital to continue advancing its next-generation AF mapping platform. - The company will keep pursuing commercialization with urgency, according to Kalil. - CoreMap will likely use the funding to support its next stage of growth and product development. - The company’s longer-term goal is to give electrophysiologists more precise guidance for AF ablation.